

**1.5 REFERENCES**

1. Aisner, J., et al., *Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study*. J Clin Oncol, 1992. **10**(8): p. 1230-6.
2. Kulkarni, S., G. Betageri, and M. Singh, *Factors affecting microencapsulation of drugs in liposomes*. Journal of microencapsulation, 1995. **12**(3): p. 229-246.
3. Lasic, D.D. and D. Papahadjopoulos, *Medical applications of liposomes*. 1998, Amsterdam ; New York: Elsevier. xiv, 779 p.
4. Winterhalter, M. and D.D. Lasic, *Liposome stability and formation: experimental parameters and theories on the size distribution*. Chem Phys Lipids, 1993. **64**(1-3): p. 35-43.
5. Fenske, D.B. and P.R. Cullis, *Entrapment of small molecules and nucleic acid-based drugs in liposomes*. Methods Enzymol, 2005. **391**: p. 7-40.
6. Maurer, N., D.B. Fenske, and P.R. Cullis, *Developments in liposomal drug delivery systems*. Expert Opin Biol Ther, 2001. **1**(6): p. 923-47.
7. Noble, C.O., et al., *Development of ligand-targeted liposomes for cancer therapy*. Expert Opin Ther Targets, 2004. **8**(4): p. 335-53.
8. Schifferers, R.M., et al., *Liposomal targeting of angiogenic vasculature*. Curr Drug Deliv, 2005. **2**(4): p. 363-8.
9. Schifferers, R.M., et al., *Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice*. Neoplasia, 2005. **7**(2): p. 118-27.
10. Bangham, A.D., M.M. Standish, and J.C. Watkins, *Diffusion of univalent ions across the lamellae of swollen phospholipids*. J Mol Biol, 1965. **13**(1): p. 238-52.
11. Batzri, S. and E.D. Korn, *Single bilayer liposomes prepared without sonication*. Biochim Biophys Acta, 1973. **298**(4): p. 1015-9.
12. Deamer, D. and A.D. Bangham, *Large volume liposomes by an ether vaporization method*. Biochim Biophys Acta, 1976. **443**(3): p. 629-34.
13. Kagawa, Y., *[Reconstitution of oxidative phosphorylation system]*. Tanpakushitsu Kakusan Koso, 1971. **16**(9): p. 775-86.
14. Barenholtz, Y., S. Amselem, and D. Lichtenberg, *A new method for preparation of phospholipid vesicles (liposomes) - French press*. FEBS Lett, 1979. **99**(1): p. 210-4.
15. Shew, R.L. and D.W. Deamer, *A novel method for encapsulation of macromolecules in liposomes*. Biochim Biophys Acta, 1985. **816**(1): p. 1-8.
16. Cortesi, R., et al., *Preparation of liposomes by reverse-phase evaporation using alternative organic solvents*. J Microencapsul, 1999. **16**(2): p. 251-6.
17. Meeren, P.V.d., et al., *Particle sizing of liposomal dispersions: a critical evaluation of some quasi-elastic light-scattering data-analysis software programs*. Journal of Liposome Research, 1992. **2**(1): p. 23-42.
18. Olson, F., et al., *Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes*. Biochim Biophys Acta, 1979. **557**(1): p. 9-23.
19. Szoka, F., et al., *Fluorescence studies on the mechanism of liposome-cell interactions in vitro*. Biochim Biophys Acta, 1980. **600**(1): p. 1-18.
20. Szoka, F., et al., *Preparation of unilamellar liposomes of intermediate size (0.1-0.2  $\mu$ mol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes*. Biochim Biophys Acta, 1980. **601**(3): p. 559-71.

21. Szoka, F., Jr. and D. Papahadjopoulos, *Comparative properties and methods of preparation of lipid vesicles (liposomes)*. Annu Rev Biophys Bioeng, 1980. **9**: p. 467-508.
22. Madden, T.D., M.J. Hope, and P.R. Cullis, *Modelling the biological membrane*. Biochem Soc Trans, 1987. **15**(1): p. 75-7.
23. Mayer, L.D., et al., *Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential*. Biochim Biophys Acta, 1985. **816**(2): p. 294-302.
24. Gabizon, A., et al., *Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model*. Br J Cancer, 1985. **51**(5): p. 681-9.
25. Segal, H.L., *Lysosomes and intracellular protein turnover*. Front Biol, 1975. **43**(4): p. 295-302.
26. Jain, M.K. and D. Zakim, *The spontaneous incorporation of proteins into preformed bilayers*. Biochim Biophys Acta, 1987. **906**(1): p. 33-68.
27. Jain, M.K. and W.L. Vaz, *Dehydration of the lipid-protein microinterface on binding of phospholipase A2 to lipid bilayers*. Biochim Biophys Acta, 1987. **905**(1): p. 1-8.
28. Forssen, E.A. and Z.A. Tokes, *Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity*. Proc Natl Acad Sci U S A, 1981. **78**(3): p. 1873-7.
29. Allen, T.M., et al., *Therapeutic liposome composition and method of preparation*. 2000, Google Patents.
30. Olson, F., et al., *Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes*. Eur J Cancer Clin Oncol, 1982. **18**(2): p. 167-76.
31. Mehta, R., et al., *Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells*. Biochim Biophys Acta, 1984. **770**(2): p. 230-4.
32. Ambegia, E., et al., *Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression*. Biochim Biophys Acta, 2005. **1669**(2): p. 155-63.
33. Mui, B., et al., *Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles*. J Pharmacol Exp Ther, 2001. **298**(3): p. 1185-92.
34. Zimmermann, R., *Médecine nucléaire la radioactivité au service du diagnostic et de la thérapie*. 2006, EDP Science,: Les Ulis. p. 1 online resource (viii, 171 p.
35. Allen, T.M. and P.R. Cullis, *Drug delivery systems: entering the mainstream*. Science, 2004. **303**(5665): p. 1818-22.
36. Jeffs, L.B., et al., *A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA*. Pharm Res, 2005. **22**(3): p. 362-72.
37. Fenske, D.B., I. MacLachlan, and P.R. Cullis, *Stabilized plasmid-lipid particles: a systemic gene therapy vector*. Methods Enzymol, 2002. **346**: p. 36-71.
38. Kale, A.A. and V.P. Torchilin, *"Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes*. J Liposome Res, 2007. **17**(3-4): p. 197-203.
39. Li, L., F.S. Braiteh, and R. Kurzrock, *Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis*. Cancer, 2005. **104**(6): p. 1322-31.
40. yw, C., *Novel drug delivery system* 2nd ed. 1992, New York: Marcel Dekker Inc.

41. Crommelin, D., Schreier H, *Liposomes*. Colloidal drug delivery systems., ed K. J. 1994, New York: Marcel Dekker. pp 73-190.
42. Vyas, S.P. and R.K. Khar, *Targeted & Controlled Drug Delivery: Novel Carrier Systems*. 1997, New Delhi: CBS publishers & distributors.
43. Jain SK, J.N., *Liposomes as drug carriers*, in *Controlled and Novel drug delivery*, J. NK, Editor. 1997, CBS Publishers: New Delhi. p. 304 – 352.
44. Amarnath Sharma, U.S.S., *Liposomes in drug delivery: progress and limitations* International Journal of Pharmaceutics, 1997. **154 (1997) 123 140**
45. Oku, N., *Anticancer therapy using glucuronate modified long-circulating liposomes*. Adv Drug Deliv Rev, 1999. **40(1-2)**: p. 63-73.
46. Willis, M. and E. Forssen, *Ligand-targeted liposomes*. Adv Drug Deliv Rev, 1998. **29(3)**: p. 249-271.
47. Ellerby, H.M., et al., *Anti-cancer activity of targeted pro-apoptotic peptides*. Nat Med, 1999. **5(9)**: p. 1032-8.
48. Arap, W., R. Pasqualini, and E. Ruoslahti, *Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model* Science, 1998. **279(5349)**: p. 377-80.
49. Arap, W., R. Pasqualini, and E. Ruoslahti, *Chemotherapy targeted to tumor vasculature*. Curr Opin Oncol, 1998. **10(6)**: p. 560-5.
50. Schiffelers, R.M., et al., *Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin*. J Control Release, 2003. **91(1-2)**: p. 115-22.
51. Brooks, P.C., et al., *Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels*. Cell, 1994. **79(7)**: p. 1157-64.
52. Friedlander, M., et al., *Definition of two angiogenic pathways by distinct alpha v integrins*. Science, 1995. **270(5241)**: p. 1500-2.
53. Hynes, R.O., *A reevaluation of integrins as regulators of angiogenesis*. Nat Med, 2002. **8(9)**: p. 918-21.
54. Gibson, K.A., et al., *Expression of the alphaEbeta7 integrin by mast cells in rheumatoid synovium*. J Rheumatol, 2000. **27(12)**: p. 2754-60.
55. Koivunen, E., B. Wang, and E. Ruoslahti, *Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins*. Biotechnology (N Y), 1995. **13(3)**: p. 265-70.
56. Mastrobattista, E., G.A. Koning, and G. Storm, *Immunoliposomes for the targeted delivery of antitumor drugs*. Adv Drug Deliv Rev, 1999. **40(1-2)**: p. 103-127.
57. Maruyama, K., et al., *Possibility of active targeting to tumor tissues with liposomes*. Adv Drug Deliv Rev, 1999. **40(1-2)**: p. 89-102.
58. Nallamothu, R., et al., *A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies*. PDA J Pharm Sci Technol, 2006. **60(3)**: p. 144-55.
59. Tripathi, D., et al., *Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis*. Am J Gastroenterol, 2004. **99(2)**: p. 390-4.
60. Allen, C., et al., *Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol)*. Biosci Rep, 2002. **22(2)**: p. 225-50.

61. Sapra, P. and T.M. Allen, *Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs*. *Cancer Res*, 2002. **62**(24): p. 7190-4.
62. Sapra, P., P. Tyagi, and T.M. Allen, *Ligand-targeted liposomes for cancer treatment*. *Curr Drug Deliv*, 2005. **2**(4): p. 369-81.
63. Samuni, A.M., A. Lipman, and Y. Barenholz, *Damage to liposomal lipids: protection by antioxidants and cholesterol-mediated dehydration*. *Chem Phys Lipids*, 2000. **105**(2): p. 121-34.
64. Fukuzawa, K., et al., *Antioxidative effect of alpha-tocopherol incorporation into lecithin liposomes on ascorbic acid-Fe<sup>2+</sup>-induced lipid peroxidation*. *Arch Biochem Biophys*, 1981. **206**(1): p. 173-80.
65. Hunt, C.A. and S. Tsang, *α-Tocopherol retards autoxidation and prolongs the shelf-life of liposomes*. *International Journal of Pharmaceutics*, 1981. **8**(2): p. 101-110.
66. Tirosh, O., et al., *Hydration of polyethylene glycol-grafted liposomes*. *Biophys J*, 1998. **74**(3): p. 1371-9.
67. Prieve, M.G., et al., *Differential importin-alpha recognition and nuclear transport by nuclear localization signals within the high-mobility-group DNA binding domains of lymphoid enhancer factor 1 and T-cell factor 1*. *Mol Cell Biol*, 1998. **18**(8): p. 4819-32.
68. Kirpotin, D., et al., *Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro*. *Biochemistry*, 1997. **36**(1): p. 66-75.
69. Goren, D., et al., *Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump*. *Clin Cancer Res*, 2000. **6**(5): p. 1949-57.
70. Eliaz, R.E. and F.C. Szoka, Jr., *Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells*. *Cancer Res*, 2001. **61**(6): p. 2592-601.
71. Zalipsky, S., et al., *Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR*. *Bioconjug Chem*, 1995. **6**(6): p. 705-8.
72. Moreira, J.N., et al., *A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer*. *Biochim Biophys Acta*, 2001. **1514**(2): p. 303-17.
73. Willis, M.C., et al., *Liposome-anchored vascular endothelial growth factor aptamers*. *Bioconjug Chem*, 1998. **9**(5): p. 573-82.
74. Tardi, P., M.B. Bally, and T.O. Harasym, *Clearance properties of liposomes involving conjugated proteins for targeting*. *Adv Drug Deliv Rev*, 1998. **32**(1-2): p. 99-118.
75. Hansen, C.B., et al., *Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures*. *Biochim Biophys Acta*, 1995. **1239**(2): p. 133-44.
76. Martin, F.J., W.L. Hubbell, and D. Papahadjopoulos, *Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds*. *Biochemistry*, 1981. **20**(14): p. 4229-38.
77. Parr, M.J., et al., *Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles*. *Biochim Biophys Acta*, 1994. **1195**(1): p. 21-30.

78. Blume, G., et al., *Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times*. *Biochim Biophys Acta*, 1993. **1149**(1): p. 180-4.
79. Maruyama, K., et al., *Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies*. *Biochim Biophys Acta*, 1995. **1234**(1): p. 74-80.
80. Gabizon, A., et al., *Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies*. *Bioconjug Chem*, 1999. **10**(2): p. 289-98.
81. Ishida, T., D.L. Iden, and T.M. Allen, *A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs*. *FEBS Lett*, 1999. **460**(1): p. 129-33.
82. Iden, D.L. and T.M. Allen, *In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach*. *Biochim Biophys Acta*, 2001. **1513**(2): p. 207-16.
83. Drummond, D.C., et al., *Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors*. *Pharmacol Rev*, 1999. **51**(4): p. 691-743.
84. Wheeler, J.J., et al., *Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol*. *J Pharm Sci*, 1994. **83**(11): p. 1558-64.
85. Stamp, D. and R.L. Juliano, *Factors affecting the encapsulation of drugs within liposomes*. *Can J Physiol Pharmacol*, 1979. **57**(5): p. 535-9.
86. Ma, L., C. Ramachandran, and N.D. Weiner, *Partitioning of a homologous series of alkyl p-aminobenzoates in dipalmitoylphosphatidylcholine liposomes: effect of liposome type*. *International journal of pharmaceuticals*, 1991. **77**(2): p. 127-140.
87. Heurtault, B., et al., *Physico-chemical stability of colloidal lipid particles*. *Biomaterials*, 2003. **24**(23): p. 4283-300.
88. Heurtault, B., et al., *The influence of lipid nanocapsule composition on their size distribution*. *Eur J Pharm Sci*, 2003. **18**(1): p. 55-61.
89. Ganapathi, R. and A. Krishan, *Effect of cholesterol content of liposomes on the encapsulation, efflux and toxicity of adriamycin*. *Biochem Pharmacol*, 1984. **33**(4): p. 698-700.
90. Taylor, K., et al., *Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes*. *International journal of pharmaceuticals*, 1990. **58**(1): p. 49-55.
91. Talsma, H., M.J. Van Steenberg, and D.J. Crommelin, *The cryopreservation of liposomes. 2. Effect of particle size on crystallization behavior and marker retention*. *Cryobiology*, 1992. **29**(1): p. 80-6.
92. Mohammed, A.R., et al., *Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability*. *Int J Pharm*, 2004. **285**(1-2): p. 23-34.
93. Cannon, J.B., et al., *Targeted delivery of a heme oxygenase inhibitor with a lyophilized liposomal tin mesoporphyrin formulation*. *Pharm Res*, 1993. **10**(5): p. 715-21.
94. Amselem, S., A. Gabizon, and Y. Barenholz, *Optimization and upscaling of doxorubicin-containing liposomes for clinical use*. *J Pharm Sci*, 1990. **79**(12): p. 1045-52.

95. Jay, M. and G.A. Digenis, *Enhanced entrapment of a quaternary ammonium compound in liposomes by ion-pairing*. J Pharm Sci, 1982. **71**(8): p. 958-60.
96. Lee, J.H., et al., *Enhanced Entrapment of Isopropamide Iodide in Liposomes by Ion-Pairing with Sodium Taurodeoxycholate*. Drug Development and Industrial Pharmacy, 1988. **14**(4): p. 451-463.
97. Lim, H.J., et al., *Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors*. J Pharmacol Exp Ther, 2000. **292**(1): p. 337-45.
98. Zuidam, N.J., et al., *Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids*. Biochim Biophys Acta, 1995. **1240**(1): p. 101-10.
99. Barenholz, Y., *Relevancy of drug loading to liposomal formulation therapeutic efficacy*. J Liposome Res, 2003. **13**(1): p. 1-8.
100. Lasic, D.D. and D. Papahadjopoulos, *Liposomes revisited*. Science, 1995. **267**(5202): p. 1275-6.
101. Bandak, S., et al., *Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models*. Anticancer Drugs, 1999. **10**(10): p. 911-20.
102. Barenholz, Y., *Liposome application: problems and prospects*. Current Opinion in Colloid & Interface Science, 2001. **6**(1): p. 66-77.
103. Lasic, D.D., *Doxorubicin in sterically stabilized liposomes*. Nature, 1996. **380**(6574): p. 561-2.
104. Harashima, H., et al., *Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes*. Pharm Res, 1994. **11**(3): p. 402-6.
105. Woodle, M.C. and D.D. Lasic, *Sterically stabilized liposomes*. Biochim Biophys Acta, 1992. **1113**(2): p. 171-99.
106. Baban, D.F. and L.W. Seymour, *Control of tumour vascular permeability*. Advanced Drug Delivery Reviews, 1998. **34**(1): p. 109-119.
107. Yuan, F., et al., *Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size*. Cancer Res, 1995. **55**(17): p. 3752-6.
108. Gabizon, A., et al., *Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies*. Cancer Res, 1990. **50**(19): p. 6371-8.
109. Gabizon, R. and S.B. Prusiner, *Prion liposomes*. Biochem J, 1990. **266**(1): p. 1-14.
110. Kirby, C., J. Clarke, and G. Gregoriadis, *Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum*. FEBS Lett, 1980. **111**(2): p. 324-8.
111. Kirby, C., J. Clarke, and G. Gregoriadis, *Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro*. Biochem J, 1980. **186**(2): p. 591-8.
112. Kirby, C. and G. Gregoriadis, *The effect of the cholesterol content of small unilamellar liposomes on the fate of their lipid components in vitro*. Life Sci, 1980. **27**(23): p. 2223-30.
113. Senior, J., et al., *Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies*

- with poly(ethylene glycol)-coated vesicles. *Biochim Biophys Acta*, 1991. **1062**(1): p. 77-82.
114. Allen, T.M., et al., *Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo*. *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 1991. **1066**(1): p. 29-36.
115. Woodle, M.C., et al., *Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential*. *Biophys J*, 1992. **61**(4): p. 902-10.
116. Blume, G. and G. Cevc, *Molecular mechanism of the lipid vesicle longevity in vivo*. *Biochim Biophys Acta*, 1993. **1146**(2): p. 157-68.
117. Torchilin, V.P., et al., *Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity*. *Biochim Biophys Acta*, 1994. **1195**(1): p. 11-20.
118. Klibanov, A.L., et al., *Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes*. *FEBS Lett*, 1990. **268**(1): p. 235-7.
119. Webb, R.J., et al., *Hydrophobic mismatch and the incorporation of peptides into lipid bilayers: a possible mechanism for retention in the Golgi*. *Biochemistry*, 1998. **37**(2): p. 673-9.
120. Webb, R.J., et al., *Transmembrane alpha-helices in phospholipid bilayers*. *Biochem Soc Trans*, 1998. **26**(3): p. S309.
121. Barenholz, Y., et al., *Stability of liposomal doxorubicin formulations: problems and prospects*. *Med Res Rev*, 1993. **13**(4): p. 449-91.
122. Grit, M. and D.J. Crommelin, *Chemical stability of liposomes: implications for their physical stability*. *Chem Phys Lipids*, 1993. **64**(1-3): p. 3-18.
123. Samuni, A.M. and Y. Barenholz, *Stable nitroxide radicals protect lipid acyl chains from radiation damage*. *Free Radic Biol Med*, 1997. **22**(7): p. 1165-74.
124. Samuni, A.M., et al., *Gamma-irradiation damage to liposomes differing in composition and their protection by nitroxides*. *Free Radic Biol Med*, 1997. **23**(7): p. 972-9.
125. Zuidam, N.J., S.S. Lee, and D.J. Crommelin, *Sterilization of liposomes by heat treatment*. *Pharm Res*, 1993. **10**(11): p. 1591-6.
126. Cullis, P.R., et al., *Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles*. *Biochim Biophys Acta*, 1997. **1331**(2): p. 187-211.
127. van Winden, E.C.A., *Freeze-Drying of Liposomes: Theory and Practice*, in *Methods in Enzymology*, D. Nejat, Editor. 2003, Academic Press. p. 99-110.
128. van Winden, E.C., W. Zhang, and D.J. Crommelin, *Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration*. *Pharm Res*, 1997. **14**(9): p. 1151-60.
129. Glavas-Dodov, M., et al., *The effects of lyophilization on the stability of liposomes containing 5-FU*. *Int J Pharm*, 2005. **291**(1-2): p. 79-86.
130. Sarbolouki, M.N. and T. Toliat, *Storage stability of stabilized MLV and REV liposomes containing sodium methotrexate (aqueous & lyophilized)*. *PDA J Pharm Sci Technol*, 1998. **52**(1): p. 23-7.
131. Komatsu, H., et al., *Effects of the acyl chain composition of phosphatidylcholines on the stability of freeze-dried small liposomes in the presence of maltose*. *Chem Phys Lipids*, 2001. **113**(1-2): p. 29-39.

132. Peer, D., A. Florentin, and R. Margalit, *Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes*. *Biochim Biophys Acta*, 2003. **1612**(1): p. 76-82.
133. Sun, K. and D. Mauzerall, *Charge transfer across a single lipid-water interface causes ion pumping across the bilayer*. *Biophys J*, 1996. **71**(1): p. 309-16.
134. Sun, K. and D. Mauzerall, *Evidence for ion chain mechanism of the nonlinear charge transport of hydrophobic ions across lipid bilayers*. *Biophys J*, 1996. **71**(1): p. 295-308.
135. Zhdanov, R.I., et al., *[New cationic liposomes for transfecting eukaryotic cells]*. *Dokl Akad Nauk*, 1998. **362**(4): p. 557-60.
136. Crowe, L.M., et al., *Preservation of freeze-dried liposomes by trehalose*. *Arch Biochem Biophys*, 1985. **242**(1): p. 240-7.
137. Harrigan, P.R., T.D. Madden, and P.R. Cullis, *Protection of liposomes during dehydration or freezing*. *Chem Phys Lipids*, 1990. **52**(2): p. 139-49.
138. Crowe, J.H., B.J. Spargo, and L.M. Crowe, *Preservation of dry liposomes does not require retention of residual water*. *Proc Natl Acad Sci U S A*, 1987. **84**(6): p. 1537-40.
139. Wolkers, W.F., et al., *Preservation of dried liposomes in the presence of sugar and phosphate*. *Biochim Biophys Acta*, 2004. **1661**(2): p. 125-34.
140. Suzuki, T., H. Komatsu, and K. Miyajima, *Effects of glucose and its oligomers on the stability of freeze-dried liposomes*. *Biochim Biophys Acta*, 1996. **1278**(2): p. 176-82.
141. Ohtake, S., et al., *Phase behavior of freeze-dried phospholipid-cholesterol mixtures stabilized with trehalose*. *Biochim Biophys Acta*, 2005. **1713**(1): p. 57-64.
142. Ugwu, S., et al., *Preparation, characterization, and stability of liposome-based formulations of mitoxantrone*. *Drug Dev Ind Pharm*, 2005. **31**(2): p. 223-9.
143. Stevens, P.J. and R.J. Lee, *Formulation kit for liposomal doxorubicin composed of lyophilized liposomes*. *Anticancer Res*, 2003. **23**(1A): p. 439-42.
144. Tannock, I.F. and D.G. Warr, *Unconventional therapies for cancer: a refuge from the rules of evidence?* *CMAJ*, 1998. **159**(7): p. 801-2.
145. Tannock, I.F., *Conventional cancer therapy: promise broken or promise delayed?* *Lancet*, 1998. **351 Suppl 2**: p. SII9-16.
146. Jang, S.H., et al., *Drug delivery and transport to solid tumors*. *Pharm Res*, 2003. **20**(9): p. 1337-50.
147. Jain, R.K., *Transport of molecules, particles, and cells in solid tumors*. *Annu Rev Biomed Eng*, 1999. **1**: p. 241-63.
148. Jain, R.K., *Barriers to drug delivery in solid tumors*. *Sci Am*, 1994. **271**(1): p. 58-65.
149. Hamberg, L.M., et al., *Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution*. *Cancer Res*, 1994. **54**(23): p. 6032-6.
150. Baxter, L.T. and R.K. Jain, *Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection*. *Microvasc Res*, 1989. **37**(1): p. 77-104.
151. Doyle, L.A., et al., *A multidrug resistance transporter from human MCF-7 breast cancer cells*. *Proc Natl Acad Sci U S A*, 1998. **95**(26): p. 15665-70.

152. Molema, G., *Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies*. Pharm Res, 2002. **19**(9): p. 1251-8.
153. Carmeliet, P. and R.K. Jain, *Angiogenesis in cancer and other diseases*. Nature, 2000. **407**(6801): p. 249-57.
154. Chaplin, D.J. and G.J. Dougherty, *Tumour vasculature as a target for cancer therapy*. Br J Cancer, 1999. **80 Suppl 1**: p. 57-64.
155. Kerbel, R.S., *Tumor angiogenesis: past, present and the near future*. Carcinogenesis, 2000. **21**(3): p. 505-15.
156. Denekamp, J., *Vascular attack as a therapeutic strategy for cancer*. Cancer Metastasis Rev, 1990. **9**(3): p. 267-82.
157. Reynolds, L.E., et al., *Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins*. Nat Med, 2002. **8**(1): p. 27-34.
158. Max, R., et al., *Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas*. Int J Cancer, 1997. **71**(3): p. 320-4.
159. Folkman, J., *Addressing tumor blood vessels*. Nat Biotechnol, 1997. **15**(6): p. 510.
160. Stacy, D.R., B. Lu, and D.E. Hallahan, *Radiation-guided drug delivery systems*. Expert Rev Anticancer Ther, 2004. **4**(2): p. 283-8.
161. Kiani, M.F., et al., *Targeting microparticles to select tissue via radiation-induced upregulation of endothelial cell adhesion molecules*. Pharm Res, 2002. **19**(9): p. 1317-22.
162. Baker, D.G. and R.J. Krochak, *The response of the microvascular system to radiation: a review*. Cancer Invest, 1989. **7**(3): p. 287-94.
163. Sikora, K., *The impact of future technology on cancer care*. Clin Med, 2002. **2**(6): p. 560-8.
164. Baker, D.G., *How significant are the risks from occupational exposure to ionizing radiation?* Appl Radiol, 1989. **18**(9): p. 19-21, 24.
165. Hallahan, D., J. Kuchibhotla, and C. Wyble, *Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium*. Cancer Res, 1996. **56**(22): p. 5150-5.
166. Hallahan, D.E., et al., *Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature*. J Control Release, 2001. **74**(1-3): p. 183-91.
167. Hallahan, D.E., et al., *Drug-radiation interactions in tumor blood vessels*. Oncology (Williston Park), 1999. **13**(10 Suppl 5): p. 71-7.
168. Jahroudi, N., A.M. Ardekani, and J.S. Greenberger, *Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells*. Blood, 1996. **88**(10): p. 3801-14.
169. Jahroudi, N., A.M. Ardekani, and J.S. Greenberger, *An NF1-like protein functions as a repressor of the von Willebrand factor promoter*. J Biol Chem, 1996. **271**(35): p. 21413-21.
170. Verheij, M., et al., *Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor*. Radiat Res, 1994. **137**(2): p. 202-7.
171. Eissner, G., et al., *Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin*. Blood, 1995. **86**(11): p. 4184-93.

172. Donnelly, E.F., et al., *Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels*. Radiology, 2001. **219**(1): p. 166-70.
173. Yu, H., et al., *A longitudinal study of radiation-induced changes in tumor vasculature by contrast-enhanced magnetic resonance imaging*. Radiat Res, 2002. **158**(2): p. 152-8.
174. Ruoslahti, E., *RGD and other recognition sequences for integrins*. Annu Rev Cell Dev Biol, 1996. **12**: p. 697-715.
175. Pierschbacher, M.D. and E. Ruoslahti, *Variants of the cell recognition site of fibronectin that retain attachment-promoting activity*. Proc Natl Acad Sci U S A, 1984. **81**(19): p. 5985-8.
176. Pierschbacher, M.D. and E. Ruoslahti, *Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule*. Nature, 1984. **309**(5963): p. 30-3.
177. Pfaff, M., *Recognition Sites of RGD-Dependent Integrins*, in *Integrin-Ligand Interaction*. 1997, Springer US. p. 101-121.
178. Ruoslahti, E., *Integrin signaling and matrix assembly*. Tumour Biol, 1996. **17**(2): p. 117-24.
179. Hersel, U., C. Dahmen, and H. Kessler, *RGD modified polymers: biomaterials for stimulated cell adhesion and beyond*. Biomaterials, 2003. **24**(24): p. 4385-415.
180. Kok, R.J., et al., *Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics*. Bioconjug Chem, 2002. **13**(1): p. 128-35.
181. Schraa, A.J., et al., *Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases*. Biotechnol Annu Rev, 2002. **8**: p. 133-65.
182. Schraa, A.J., et al., *Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting*. J Control Release, 2002. **83**(2): p. 241-51.
183. Schraa, A.J., et al., *Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study*. Int J Cancer, 2002. **102**(5): p. 469-75.
184. Schiffelers, R.M., et al., *Ligand-targeted liposomes directed against pathological vasculature*. J Liposome Res, 2002. **12**(1-2): p. 129-35.
185. Schiffelers, R.M., et al., *Targeting of liposomes to angiogenic endothelial cells*. Cell Mol Biol Lett, 2002. **7**(2): p. 255.
186. Pfaff, M., et al., *Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins*. J Biol Chem, 1994. **269**(32): p. 20233-8.
187. Aumailley, M., et al., *Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1*. FEBS Lett, 1991. **291**(1): p. 50-4.
188. Haubner, R., et al., *Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin  $\alpha V \beta 3$  Antagonists*. Journal of the American Chemical Society, 1996. **118**(32): p. 7461-7472.
189. Haubner, R. and C. Decristoforo, *Radiolabelled RGD peptides and peptidomimetics for tumour targeting*. Front Biosci (Landmark Ed), 2009. **14**: p. 872-86.

## CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW

---

190. Haubner, R., et al., *Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression*. *Nuklearmedizin*, 2004. **43**(1): p. 26-32.
191. Jiang, J., et al., *Synthesis of RGD analogs as potential vectors for targeted drug delivery*. *Bioorg Chem*, 2001. **29**(6): p. 357-79.
192. N.N. *Gemzar*. 2009c; Available from: <http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=41213>. .
193. Massing, U. and S. Fuxius, *Liposomal formulations of anticancer drugs: selectivity and effectiveness*. *Drug Resist Updat*, 2000. **3**(3): p. 171-177.
194. Brandl, M., *Liposomes as drug carriers: a technological approach*. *Biotechnol Annu Rev*, 2001. **7**: p. 59-85.

## CHAPTER 2: ANALYTICAL METHOD DEVELOPMENT

---

### 2.8 References

1. Singh R, *HPLC method development and validation - an overview*. *Journal of Pharmaceutical Education and Research*, 2013. 4(1): p. 26-33
2. J.V.L.N. SESHAGIRI RAO\*, M.M.K.P.B.Pa.P.R.K., *RP-HPLC Analysis of Gemcitabine in Pure Form and in Pharmaceutical Dosage Forms*. *Asian Journal of Chemistry*, 2007. **19**(5): p. 3399-3402.
3. Lin N M, Z.S., Sheng-lin M, Fan Y, Zhong H J and Fang L, *Acta Pharma Sinica*, 2004. **25**(12): p. 1584-1589.
4. Swartz, M.E. and I.S. Krull, *Handbook of Analytical Validation*. 2012: Taylor & Francis.
5. *USP NF-30*

1. Bangham, A.D., M.M. Standish, and J.C. Watkins, *Diffusion of univalent ions across the lamellae of swollen phospholipids*. J Mol Biol, 1965. **13**(1): p. 238-52.
2. Vemuri, S. and C.T. Rhodes, *Preparation and characterization of liposomes as therapeutic delivery systems: a review*. Pharmaceutica Acta Helvetiae, 1995. **70**(2): p. 95-111.
3. Chatterjee, S. and D.K. Banerjee, *Preparation, isolation, and characterization of liposomes containing natural and synthetic lipids*. Methods Mol Biol, 2002. **199**: p. 3-16.
4. Patel, G.B. and G.D. Sprott, *Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems*. Crit Rev Biotechnol, 1999. **19**(4): p. 317-57.
5. Voinea, M. and M. Simionescu, *Designing of 'intelligent' liposomes for efficient delivery of drugs*. J Cell Mol Med, 2002. **6**(4): p. 465-74.
6. Salem, II, D.L. Flasher, and N. Duzgunes, *Liposome-encapsulated antibiotics*. Methods Enzymol, 2005. **391**: p. 261-91.
7. Bakker-Woudenberg, I.A., et al., *Long-circulating sterically stabilized liposomes in the treatment of infections*. Methods Enzymol, 2005. **391**: p. 228-60.
8. Abraham, S.A., et al., *The liposomal formulation of doxorubicin*. Methods Enzymol, 2005. **391**: p. 71-97.
9. Schneider, M., et al., *Method for making liposomes of enhanced entrapping capacity toward foreign substances to be encapsulated*. 1992, Google Patents.
10. Szoka, F. and D. Papahadjopoulos, *Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation*. Proceedings

- of the National Academy of Sciences of the United States of America, 1978. **75**(9): p. 4194-4198.
11. Kirby, C. and G. Gregoriadis, *Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes*. Nat Biotech, 1984. **2**(11): p. 979-984.
  12. Shew, R.L. and D.W. Deamer, *A novel method for encapsulation of macromolecules in liposomes*. Biochim Biophys Acta, 1985. **816**(1): p. 1-8.
  13. Zhai, G., et al., *A transferrin receptor-targeted liposomal formulation for docetaxel*. J Nanosci Nanotechnol, 2010. **10**(8): p. 5129-36.
  14. Naik, S., et al., *Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology*. The Journal of Supercritical Fluids, 2010. **54**(1): p. 110-119.
  15. Grosse, P.Y., F. Bressolle, and F. Pinguet, *In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin*. Eur J Cancer, 1998. **34**(1): p. 168-74.
  16. Hwang, H.Y., et al., *Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles*. J Control Release, 2008. **128**(1): p. 23-31.
  17. Li, X., et al., *Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate*. Eur J Pharm Biopharm, 2008. **70**(3): p. 726-34.
  18. Xu, Z., et al., *The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma*. Biomaterials, 2009. **30**(2): p. 226-32.
  19. Li, X., et al., *Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers*. J Pharm Pharmacol, 2009. **61**(11): p. 1485-92.
  20. Oku, N., *Anticancer therapy using glucuronate modified long-circulating liposomes*. Adv Drug Deliv Rev, 1999. **40**(1-2): p. 63-73.
  21. Lundberg, B.B., G. Griffiths, and H.J. Hansen, *Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin*. Int J Pharm, 2000. **205**(1-2): p. 101-8.
  22. Manjappa, A.S., et al., *Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor*. J Control Release, 2011. **150**(1): p. 2-22.
  23. Colombo, M. and A. Bianchi, *Click chemistry for the synthesis of rgd-containing integrin ligands*. Molecules, 2010. **15**(1): p. 178-197.
  24. Pierschbacher, M.D. and E. Ruoslahti, *Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule*. Nature, 1983. **309**(5963): p. 30-33.

25. Hynes, R.O., *Integrins: a family of cell surface receptors*. *cell*, 1987. **48**(4): p. 549-554.
26. Yamada, K.M. and B. Geiger, *Molecular interactions in cell adhesion complexes*. *Current opinion in cell biology*, 1997. **9**(1): p. 76-85.
27. Humphries, J.D., A. Byron, and M.J. Humphries, *Integrin ligands at a glance*. *Journal of cell science*, 2006. **119**(19): p. 3901-3903.
28. Temming, K., et al., *RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature*. *Drug resistance updates*, 2005. **8**(6): p. 381-402.
29. Wang, F., et al., *The Functions and Applications of RGD in Tumor Therapy and Tissue Engineering*. *International Journal of Molecular Sciences*, 2013. **14**(7): p. 13447.
30. Zhang, Y.F., et al., *Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies*. *Eur J Pharm Biopharm*, 2010. **74**(3): p. 467-73.
31. Dubey, P.K., et al., *Liposomes modified with cyclic RGD peptide for tumor targeting*. *J Drug Target*, 2004. **12**(5): p. 257-64.
32. Hottot, A., S. Vessot, and J. Andrieu, *Determination of mass and heat transfer parameters during freeze-drying cycles of pharmaceutical products*. *PDA J Pharm Sci Technol*, 2005. **59**(2): p. 138-53.
33. Daoussi, R., et al., *Sublimation kinetics and sublimation end-point times during freeze-drying of pharmaceutical active principle with organic co-solvent formulations*. *Chemical Engineering Research and Design*, 2009. **87**(7): p. 899-907.
34. Choi, M.-J., et al., *Effect of a High-Pressure-Induced Freezing Process on the Stability of Freeze-Dried Nanocapsules*. *Drying Technology*, 2008. **26**(10): p. 1199-1207.
35. Hawe, A. and W. Friess, *Impact of freezing procedure and annealing on the physico-chemical properties and the formation of mannitol hydrate in mannitol-sucrose-NaCl formulations*. *Eur J Pharm Biopharm*, 2006. **64**(3): p. 316-25.
36. Franks, F., *Freeze-drying of bioproducts: putting principles into practice*. *European Journal of Pharmaceutics and Biopharmaceutics*, 1998. **45**(3): p. 221-229.
37. Pikal, M.J., et al., *The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure*. *International Journal of Pharmaceutics*, 1990. **60**(3): p. 203-207.
38. Torchilin, V. and V. Weissig, *Liposomes: A Practical Approach*. 2003: OUP Oxford.
39. van Winden, E.C., W. Zhang, and D.J. Crommelin, *Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration*. *Pharm Res*, 1997. **14**(9): p. 1151-60.

40. Yang, S., et al., *Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency*. Int J Pharm, 2012. **434**(1-2): p. 155-60.
41. FJ., M., *Pharmaceutical Manufacturing of Liposomes*, in *Specialized Drug Delivery Systems, Manufacturing and Production Technology*, P. Tyle, Editor. 1990, M. Dekker, Inc.: New York. p. 267-316.
42. de Gier, J., J.G. Mandersloot, and L.L. van Deenen, *Lipid composition and permeability of liposomes*. Biochim Biophys Acta, 1968. **150**(4): p. 666-75.
43. Sułkowski, W.W., et al., *The influence of temperature, cholesterol content and pH on liposome stability*. Journal of Molecular Structure, 2005. **744-747**(0): p. 737-747.
44. Knoll, G., et al., *Fusion of liposomes with the plasma membrane of epithelial cells: fate of incorporated lipids as followed by freeze fracture and autoradiography of plastic sections*. J Cell Biol, 1988. **107**(6 Pt 2): p. 2511-21.
45. Chen, J., et al., *Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin*. Drug Dev Ind Pharm, 2006. **32**(6): p. 719-26.
46. Kan, P., et al., *A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect*. J Drug Deliv, 2011. **2011**: p. 629234.
47. JAVERI, I. and K. Nellaiappan, *Methods for the preparation of liposomes comprising docetaxel*. 2013, Google Patents.
48. Gregoriadis, G. and C. Davis, *Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells*. Biochem Biophys Res Commun, 1979. **89**(4): p. 1287-93.
49. Gregoriadis, G. and J. Senior, *Control of fate and behaviour of liposomes in vivo*. Prog Clin Biol Res, 1982. **102 pt A**: p. 263-79.
50. Senior, J. and G. Gregoriadis, *Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components*. Life Sci, 1982. **30**(24): p. 2123-36.
51. Chobanian, J.V., A.R. Tall, and P.I. Brecher, *Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoprotein*. Biochemistry, 1979. **18**(1): p. 180-7.
52. Damen, J., et al., *Effect of lipoprotein-free plasma on the interaction of human plasma high density lipoprotein with egg yolk phosphatidylcholine liposomes*. Biochim Biophys Acta, 1980. **620**(1): p. 90-9.
53. Maurer, N., D.B. Fenske, and P.R. Cullis, *Developments in liposomal drug delivery systems*. Expert Opin Biol Ther, 2001. **1**(6): p. 923-47.

54. Hong, M.S., et al., *Prolonged blood circulation of methotrexate by modulation of liposomal composition*. Drug Deliv, 2001. **8**(4): p. 231-7.
55. Maeda, H., T. Sawa, and T. Konno, *Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS*. J Control Release, 2001. **74**(1-3): p. 47-61.

## CHAPTER 4. IN VITRO CHARACTERIZATION

1. Berridge, M.V., P.M. Herst, and A.S. Tan, *Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction*. *Biotechnol Annu Rev*, 2005. **11**: p. 127-52.
2. Berridge, M.V. and A.S. Tan, *Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction*. *Arch Biochem Biophys*, 1993. **303**(2): p. 474-82.
3. Van Dilla, M.A., et al., *Cell microfluorometry: a method for rapid fluorescence measurement*. *Science*, 1969. **163**(3872): p. 1213-4.
4. Lauer, S.A. and J.P. Nolan, *Development and characterization of Ni-NTA-bearing microspheres*. *Cytometry*, 2002. **48**(3): p. 136-45.
5. Baserga, R., *13 - Recombinant DNA Approaches to Studying Control of Cell Proliferation: An Overview*, in *Recombinant Dna and Cell Proliferation*, G.S.S.L. Stein, Editor. 1984, Academic Press. p. 337-350.
6. Hochhauser, S.J., J.L. Stein, and G.S. Stein, *Gene expression and cell cycle regulation*. *Int Rev Cytol*, 1981. **71**: p. 95-243.
7. Baserga, R., *Growth in size and cell DNA replication*. *Exp Cell Res*, 1984. **151**(1): p. 1-5.
8. Tyson, J.J., *The coordination of cell growth and division — intentional or incidental?* *BioEssays*, 1985. **2**(2): p. 72-77.
9. Kerker, M., et al., *Is the central dogma of flow cytometry true: that fluorescence intensity is proportional to cellular dye content?* *Cytometry*, 1982. **3**(2): p. 71-8.
10. Danhier, F., A. Le Breton, and V. Preat, *RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis*. *Mol Pharm*, 2012. **9**(11): p. 2961-73.
11. Beppler, G., et al., *RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer*. *J Clin Oncol*, 2006. **24**(29): p. 4731-7.
12. Lyseng-Williamson, K.A. and C. Fenton, *Docetaxel: a review of its use in metastatic breast cancer*. *Drugs*, 2005. **65**(17): p. 2513-31.
13. Saloustros, E., D. Mavroudis, and V. Georgoulas, *Paclitaxel and docetaxel in the treatment of breast cancer*. *Expert Opin Pharmacother*, 2008. **9**(15): p. 2603-16.
14. McGuire, W.P., 3rd and M. Markman, *Primary ovarian cancer chemotherapy: current standards of care*. *Br J Cancer*, 2003. **89 Suppl 3**: p. S3-8.
15. Lim, S.K., et al., *Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice*. *Drug Dev Ind Pharm*, 2014. **40**(4): p. 470-6.
16. Hossann, M., et al., *In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes*. *Biochim Biophys Acta*, 2007. **1768**(10): p. 2491-9.
17. Kneidl, B., et al., *Thermosensitive liposomal drug delivery systems: state of the art review*. *Int J Nanomedicine*, 2014. **9**: p. 4387-98.
18. Grull, H. and S. Langereis, *Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound*. *J Control Release*, 2012. **161**(2): p. 317-27.
19. Lundbaek, J.A. and O.S. Andersen, *Lysophospholipids modulate channel function by altering the mechanical properties of lipid bilayers*. *J Gen Physiol*, 1994. **104**(4): p. 645-73.
20. Niki, E., et al., *Oxidative hemolysis of erythrocytes and its inhibition by free radical scavengers*. *J Biol Chem*, 1988. **263**(36): p. 19809-14.
21. Oku, N. and Y. Namba, *Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents*. *Methods Enzymol*, 2005. **391**: p. 145-62.
22. Bierbaum, T.J., S.R. Bouma, and W.H. Huestis, *A mechanism of erythrocyte lysis by lysophosphatidylcholine*. *Biochim Biophys Acta*, 1979. **555**(1): p. 102-10.
23. Tanaka, Y., et al., *Mechanism of human erythrocyte hemolysis induced by short-chain phosphatidylcholines and lysophosphatidylcholine*. *J Biochem*, 1983. **94**(3): p. 833-40.

24. Grit, M. and D.J. Crommelin, *Chemical stability of liposomes: implications for their physical stability*. Chem Phys Lipids, 1993. **64**(1-3): p. 3-18.
25. Heurtault, B., et al., *Physico-chemical stability of colloidal lipid particles*. Biomaterials, 2003. **24**(23): p. 4283-300.
26. Zuidam, N.J. and D.J.A. Crommelin, *Differential scanning calorimetric analysis of dipalmitoylphosphatidylcholine-liposomes upon hydrolysis*. International Journal of Pharmaceutics, 1995. **126**(1-2): p. 209-217.
27. Zuidam, N.J., et al., *Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids*. Biochim Biophys Acta, 1995. **1240**(1): p. 101-10.
28. Bosch, F.H., et al., *Characteristics of red blood cell populations fractionated with a combination of counterflow centrifugation and Percoll separation*. Blood, 1992. **79**(1): p. 254-60.
29. Prete, P.S., et al., *Quantitative assessment of human erythrocyte membrane solubilization by Triton X-100*. Biophys Chem, 2002. **97**(1): p. 1-5.
30. Ding, H., et al., *Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers*. Nanotechnology, 2011. **22**(16): p. 165101.
31. Wang, W., et al., *Protective effect of PEGylation against poly(amidoamine) dendrimer-induced hemolysis of human red blood cells*. J Biomed Mater Res B Appl Biomater, 2010. **93**(1): p. 59-64.
32. Elimelech, M., *Particle deposition and aggregation : measurement, modelling, and simulation*. Colloid and surface engineering series. 1995, Oxford England ; Boston: Butterworth-Heinemann. xv, 441 p.
33. Gregory, J., *Monitoring particle aggregation processes*. Adv Colloid Interface Sci, 2009. **147-148**: p. 109-23.
34. Holthoff, H., et al., *Measurement of Absolute Coagulation Rate Constants for Colloidal Particles: Comparison of Single and Multiparticle Light Scattering Techniques*. J Colloid Interface Sci, 1997. **192**(2): p. 463-70.
35. Lin, M.Y., et al., *Universality in colloid aggregation*. Nature, 1989. **339**(6223): p. 360-362.

## CHAPTER 5: IN VIVO TOXICITY STUDY

1. OECD GUIDELINE FOR TESTING OF CHEMICALS Fixed Dose Procedure, Guideline 420, 1-14 (2001).
2. OECD GUIDELINE FOR TESTING OF CHEMICALS Up-and-Down Procedure, Guideline 425, 1-14 (2001).
3. Whitehead A, Curnow RN. Statistical evaluation of the fixed-dose procedure. *Food and Chemical Toxicology*. 1992 4//;30(4):313-24.
4. Lipnick RL, Cotruvo JA, Hill RN, Bruce RD, Stitzel KA, Walker AP, et al. Comparison of the up-and-down, conventional LD50, and fixed-dose acute toxicity procedures. *Food Chem Toxicol*. 1995 Mar;33(3):223-31.
5. Festing MF. The design and statistical analysis of animal experiments. *ILAR J*. 2002;43(4):191-3.
6. IUPAC. Compendium of Chemical Terminology netGBCbADMaAWBSP, Oxford (1997). XML on-line corrected version: <http://goldbook.iupac.org> (2006-) created by M. Nic, J. Jirat, B. Kosata; updates compiled by A. Jenkins. ISBN 0-9678550-9-8. doi:10.1351/goldbook.
7. Chan PK, Hayes AW. Acute Toxicity and Eye Irritation. In: Hayes AW, editor. *Principles and Methods of Toxicology*. New York, US: Raven Press, Ltd.; 1994.

## CHAPTER 6. STABILITY STUDIES

1. Grit M, Crommelin DJ. The effect of aging on the physical stability of liposome dispersions. *Chemistry and physics of lipids*. 1992 Sep;62(2):113-22.
2. Cliff RO, Ligler F, Goins B, Hoffmann PM, Spielberg H, Rudolph AS. Liposome encapsulated hemoglobin: long-term storage stability and in vivo characterization. *Biomaterials, artificial cells, and immobilization biotechnology*. 1992;20(2-4):619-26.
3. Fang JY, Lin HH, Hsu LR, Tsai YH. Characterization and stability of various liposome-encapsulated enoxacin formulations. *Chemical & pharmaceutical bulletin*. 1997 Sep;45(9):1504-9. PubMed PMID: 9332003. Epub 1997/10/23. eng.
4. Slabbert C, Plessis LH, Kotze AF. Evaluation of the physical properties and stability of two lipid drug delivery systems containing mefloquine. *Int J Pharm*. 2011 May 16;409(1-2):209-15.
5. Mowri H, Nojima S, Inoue K. Effect of lipid composition of liposomes on their sensitivity to peroxidation. *Journal of biochemistry*. 1984 Feb;95(2):551-8.
6. Grit M, Zuidam NJ, Underberg WJ, Crommelin DJ. Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics. *J Pharm Pharmacology*. 1993 Jun;45(6):490-5.
7. Frokjaer S, Hjorth EL, Worts O. Stability testing of liposomes during storage. In: Gregoriadis G, editor. *Liposome Technology: Preparation of Liposomes*. Boca Raton, Florida, US: CRC Press; 1984. p. 235-45.

8. Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability—A step closer from promising technology to application. *J Control Release*. 2011 5/10/;151(3):246-55.
9. Cherng JY, Talsma H, Crommelin DJ, Hennink WE. Long term stability of poly((2-dimethylamino)ethyl methacrylate)-based gene delivery systems. *Pharm. Res.* 1999 Sep;16(9):1417-23.
10. Kasper JC, Troiber C, Kuchler S, Wagner E, Friess W. Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes. *Eur J Pharm Biopharm.* 2013 Oct;85(2):294-305.
11. Tang X, Pikal M. Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice. *Pharm Res.* 2004;21(2):191-200.
12. Shah SP, Misra A. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. *AAPS PharmSciTech.* 2004;5(4):e65.
13. Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. *Eur J of Pharm and Biopharm.* 2006 Jun;63(2):87-94.
14. Chan HK, Clark AR, Feeley JC, Kuo MC, Lehrman SR, Pikal-Cleland K, et al. Physical stability of salmon calcitonin spray-dried powders for inhalation. *J Pharm Sci.* 2004 Mar;93(3):792-804.
15. Mattern M, Winter G, Kohnert U, Lee G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. *Pharm Dev. Tech.* 1999 May;4(2):199-208.
16. Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application. *Journal of controlled release*, 2011 May 10;151(3):246-55.
17. Claus S. Novel dry powder inhalation system based on dispersion of lyophilisates: Ludwig Maximilian University of Munich; 2012.